Details

Autor(en) / Beteiligte

• Jamme, Philippe
• Descarpentries, Clotilde
• Gervais, Radj
• Dansin, Eric
• Wislez, Marie
• Grégoire, Valérie
• Richard, Nicolas
• Baldacci, Simon
• Rabbe, Nathalie
• Kyheng, Maeva
• Kherrouche, Zoulika
• Escande, Fabienne
• Copin, Marie Christine
• Cortot, Alexis B.

Titel

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice

Ist Teil von

• Clinical lung cancer, 2019-07, Vol.20 (4), p.297-304.e1

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of ALK-rearranged non–small-cell lung cancer (NSCLC), but the disease eventually progresses in all patients. In many cases, resistance to ALK TKIs arises through ALK mutations. Although clinical and biological data suggest variations in TKI efficacy according to the mechanism of resistance, ALK mutations are still rarely investigated in routine practice. We performed a retrospective multicentric study with an aim to determine the frequency and clinical relevance of ALK alterations detected using targeted next-generation sequencing in patients with advanced ALK-rearranged NSCLC after progression during an ALK TKI treatment. Data on clinical, pathological, and molecular characteristics and patient outcomes were collected. We identified 23 patients with advanced ALK-rearranged NSCLC who, between January 2012 and May 2017, had undergone at least 1 repeat biopsy at progression during an ALK TKI treatment. A resistance mechanism was identified in 9 of the 23 patients (39%). The anomalies involved included 9 ALK mutations in 8 patients and one ALK amplification. The ALK mutation rate was 15% after failure of a first ALK TKI and 33% after failure of 2 ALK TKI treatments. Five of 7 patients who received a different ALK TKI after detection of an ALK mutation achieved an objective response. All of the patients who received a TKI presumed to act on the detected ALK mutant achieved disease control. Targeted next-generation sequencing is suitable for detecting ALK resistance mutations in ALK-rearranged NSCLC patients in routine practice. It might help select the best treatment at the time of disease progression during treatment with an ALK TKI. Anaplastic lymphome kinase (ALK) mutations are responsible for resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged non–small-cell lung cancer but their frequency and relevance has not been assessed in routine practice. In this retrospective multicenter study, the ALK mutation rate was 15% and 33% after failure of treatment with 1 and 2 TKIs, respectively. Most of the patients harboring an ALK mutation achieved an objective response with subsequent ALK TKI treatment.